Marshall Wace LLP Acquires New Shares in Altimmune, Inc. (NASDAQ:ALT)

Marshall Wace LLP bought a new stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 65,517 shares of the company's stock, valued at approximately $472,000. Marshall Wace LLP owned about 0.09% of Altimmune as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ALT. Invesco Ltd. raised its position in Altimmune by 679.2% during the 4th quarter. Invesco Ltd. now owns 247,086 shares of the company's stock worth $1,781,000 after purchasing an additional 215,375 shares during the last quarter. Wells Fargo & Company MN lifted its stake in shares of Altimmune by 69.3% in the fourth quarter. Wells Fargo & Company MN now owns 215,538 shares of the company's stock worth $1,554,000 after acquiring an additional 88,209 shares during the period. Hennion & Walsh Asset Management Inc. boosted its holdings in Altimmune by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 205,590 shares of the company's stock valued at $1,482,000 after acquiring an additional 31,482 shares during the last quarter. Wellington Management Group LLP increased its position in Altimmune by 4.1% during the 4th quarter. Wellington Management Group LLP now owns 205,233 shares of the company's stock valued at $1,480,000 after purchasing an additional 8,001 shares during the period. Finally, Barclays PLC raised its holdings in Altimmune by 1.1% during the 4th quarter. Barclays PLC now owns 157,528 shares of the company's stock worth $1,135,000 after purchasing an additional 1,787 shares during the last quarter. 78.05% of the stock is owned by institutional investors.

Altimmune Trading Down 5.9 %

Altimmune stock traded down $0.34 during trading on Monday, hitting $5.43. 2,168,668 shares of the company were exchanged, compared to its average volume of 2,854,651. The business's 50 day moving average is $5.15 and its 200 day moving average is $6.64. Altimmune, Inc. has a 52 week low of $3.55 and a 52 week high of $11.16. The company has a market capitalization of $418.19 million, a P/E ratio of -3.50 and a beta of 1.13.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Equities analysts expect that Altimmune, Inc. will post -1.35 EPS for the current year.

Insider Transactions at Altimmune

In related news, CFO Gregory L. Weaver bought 10,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were purchased at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 4.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ALT shares. William Blair reissued a "market perform" rating on shares of Altimmune in a research note on Friday, March 14th. Stifel Nicolaus started coverage on shares of Altimmune in a report on Wednesday, January 8th. They set a "buy" rating and a $18.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $12.00 target price on shares of Altimmune in a research report on Thursday, April 3rd. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $20.83.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.